VBX-100 / Range Impact - LARVOL DELTA

MALACHITE INNOVATIONS ANNOUNCES TWO GRANTED U.S. PATENTS AND NEW PCT PATENT FILING (GlobeNewswire) - "Graphium Biosciences has been granted a patent by the USPTO for its 'Cannabinoid Glycoside Prodrugs and Methods of Synthesis' that involves its invention of cannabinoid glycosides and methods of targeted delivery for the treatment of gastrointestinal disorders, including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Based on our PCT application filed in 2016, our granted patent covers the first 18 distinct cannabinoid glycosides based on cannabidiol (CBD), tetrahydrocannabinol (THC), cannabidivarin (CBDV), and cannabinol (CBN), and serves as the cornerstone of our intellectual property portfolio of cannabinoid prodrugs."

Patent • Inflammatory Bowel Disease

Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Institutional Investor (GlobeNewswire) - "Vitality Biopharma, Inc...announced that the Company had entered into a definitive agreement with an institutional investor for a $5,000,000 equity line financing...The Company anticipates using the proceeds from the offering to advance the Company’s leading prodrug candidate, VBX-100, through its pre-clinical studies and for general corporate purposes."

Financing • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis